文献速递肝病

脂肪酸合成酶抑制剂TVB-2640降低代谢异常男性肝脏新生脂肪生成

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities.
PubMed 文献 · Hepatology · 2020-05-07

结果显示空腹DNL最高降低90%(P=0.003),丙氨酸氨基转移酶降低15.8±8.4%(P=0.05),药物耐受性良好,支持其治疗非酒精性脂肪性肝病的潜力。

要点

  • TVB-2640可使肥胖代谢异常男性空腹肝脏DNL降低达90%。
  • TVB-2640血药浓度升高与果糖刺激后DNL峰值百分比及6小时曲线下面积进行性降低相关。
  • 丙氨酸氨基转移酶降低15.8±8.4%,药物总体耐受良好,2例脱发停药后逆转。

核心结论

  • 脂肪酸合成酶抑制剂TVB-2640在肥胖伴代谢异常男性中显著降低肝脏新生脂肪生成,支持其治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎的潜力。

研究设计与样本

  • 采用1-13C1-乙酸静脉输注同位素标记法,口服果糖/葡萄糖负荷前后测量肝脏DNL,并通过气相色谱质谱法测定标记的极低密度脂蛋白棕榈酸酯。
  • 通过间接测热法测量底物氧化。

主要发现

  • 空腹DNL降低最高达90%(P=0.003)。
  • TVB-2640血浆浓度升高与果糖刺激后DNL峰值百分比进行性降低相关(R²=-0.749,P=0.0003),与果糖/葡萄糖负荷后6小时DNL绝对曲线下面积降低相关(R²=-0.554,P=0.005)。
  • 全部受试者丙氨酸氨基转移酶降低15.8±8.4%(P=0.05)。
  • 底物氧化无变化,药物耐受良好,血浆甘油三酯未升高;2例出现脱发,停药后逆转;空腹血糖、胰岛素、酮体和肾功能未见变化。

临床怎么用

  • TVB-2640可作为非酒精性脂肪性肝病和非酒精性脂肪性肝炎的潜在靶向治疗药物,需进一步开展更大规模临床试验验证疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Elevated hepatic de novo lipogenesis (DNL) is a key distinguishing characteristic of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis. In rodent models of NAFLD, treatment with a surrogate of TVB-2640, a pharmacological fatty acid synthase inhibitor, has been shown to reduce hepatic fat and other biomarkers of DNL. The purpose of this phase I clinical study was to test the effect of the TVB-2640 in obese men with certain metabolic abnormalities that put them at risk for NAFLD. APPROACH AND RESULTS: Twelve subjects (mean ± SEM, 42 ± 2 years, body mass index 37.4 ± 1.2 kg/m2 , glucose 103 ± 2 mg/dL, triacylglycerols 196 ± 27 mg/dL, and elevated liver enzymes) underwent 10 days of treatment with TVB-2640 at doses ranging from 50-150 mg/day. Food intake was controlled throughout the study. Hepatic DNL was measured before and after an oral fructose/glucose bolus using isotopic labeling with 1-13 C1 -acetate intravenous infusion, followed by measurement of labeled very low-density lipoprotein palmitate via gas chromatography mass spectometry. Substrate oxidation was measured by indirect calorimetry. Across the range of doses, fasting DNL was reduced by up to 90% (P = 0.003). Increasing plasma concentrations of TVB-2640 were associated with progressive reductions in the percent of fructose-stimulated peak fractional DNL (R2 = -0.749, P = 0.0003) and absolute DNL area under the curve 6 hours following fructose/glucose bolus (R2 = -0.554, P = 0.005). For all subjects combined, alanine aminotransferase was reduced by 15.8 ± 8.4% (P = 0.05). Substrate oxidation was unchanged, and safety monitoring revealed that the drug was well tolerated, without an increase in plasma triglycerides. Alopecia occurred in 2 subjects (reversed after stopping the drug), but otherwise no changes were observed in fasting glucose, insulin, ketones, and renal function. CONCLUSION: These data support the therapeutic potential of a fatty acid synthase inhibitor, TVB-2640 in particular, in patients with NAFLD and nonalcoholic steatohepatitis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Syed-Abdul MM, Parks EJ, Gaballah AH, et al. Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020. PMID: 31630414. doi:10.1002/hep.31000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。